![Corporate Overview]( "Corporate Overview")
Corporate Introduction
GenScript Biotech Corporation (HK.1548) is the world’s leading technology and service provider of
life science R&D and manufacture. Built upon its solid gene synthesis technology, GenScript Biotech is divided
into four major platforms including the life science service and product platform, the biologics contract
development and manufacturing organization (CDMO) platform, the industrial synthetic products platform, and the
integrated global cell therapy platform.
Read More »
GenScript Biotech was founded in New Jersey, US in 2002 and listed on
the Hong Kong Stock Exchange in 2015. GenScript Biotech's business operations span over 100 countries and regions
worldwide with legal entities located in the US, Mainland China, Hong Kong, China, Japan, Singapore, Netherlands,
Ireland, the United Kingdom, Korea, and Belgium. GenScript Biotech provides premium, convenient and reliable
services and products for over 200,000 customers.
As of June 30, 2023, GenScript Biotech had more than 6,400 employees
globally. In addition, GenScript Biotech owns a number of intellectual property rights, including over 240
patents, over 900 pending patent applications and great numbers of trade secrets.
Driven by the corporate mission of “make people and nature healthier
through biotechnology”, GenScript Biotech strives to become the most trustworthy biotech company in the world. As
of June 30, 2023, 85,100 peer-reviewed journal articles worldwide have cited GenScript Biotech’s services and
products.
- Culture of innovation
- Proven track record of incubating internal unicorns
- A portfolio of businesses that leverage each other's strength
- 200K+ customers in over 100 countries
- Global sales, manufacturing and R&D presence in China, US, Europe and Asia
Pacific
- Proprietary technology across all business lines
- GenScript Biotech owns a number of intellectual property rights, including
over 240 patents, over 900 pending patent applications and great
numbers of trade secrets *
- More than 6,400 employees globally
- Over 800 R&D employees
* As of June 30th, 2023
Corporate History
- 2022 Legend Biotech‘s CARVYKTI™ (cilta-cel) received U.S. FDA approval, conditional approval
by the European
- Commission (EC) and approval by Japan’s Ministry of Health, Labor and Welfare (MHLW)
- China's largest commercial GMP plasmid manufacturing facility officially established by ProBio
in Zhenjiang, Jiangsu
- Singapore manufacturing and R&D center was put into operation
- Hillhouse Capital invested over US$ 1 billion in the Group and Legend Biotech
- cPass™ SARS-CoV-2 neutralization antibody detection kit and its sVNT serological
detection method both received the notices of allowance of US patent application
- Provided plasmid products and services for the first batch of COVID-19 mRNA vaccine
projects
- Legend Biotech submitted NDA for cilta-cel in Japan
- China's largest commercial GMP plasmid manufacturing facility launched
- Developed the world's first cPass™ SARS-CoV-2 neutralization antibody fast detection
kit with Singapore to jointly fight COVID-19
- Legend Biotech listed on NASDAQ, the largest IPO for a biotech segment year to date
- cilta-cel was granted China‘s first “breakthrough therapy designation” and submitted BLA to
FDA US
- Biologics CDMO business unit launched its brand name, ProBio
- Launched New Biologics GMP CDMO R&D center
- Established European & Asia-Pacific Division
- cilta-cel received Orphan Drug Designation (FDA) & PRIME Designation
(EMA), US phase 1b data at ASH 2019: ORR 100%
- cilta-cel received IND clearance in US and China, progressing
smoothly in both US & China
- Biologics CDMO segment officially established
- Legend and Janssen entered into collaboration on cilta-cel (BCMA program)
- CFDA accepted the IND application by Legend Biotech
- Acquired CustomArray
- GenScript Biotech listed in HKEX (HK.1548)
- Launched Legend Biotech (the Cell Therapy Segment)
- CRO Leadership award
- Launched the Bestzyme (Biotech industrial synthetic biology) product segment
- New research and production facility opened in Nanjing
- Selected as the sole business entity to participate in the Synthetic Yeast Genome Sc2.0
Project
- Established subsidiary in Japan
- KPCB / TBIG Healthcare investment
- Introduced Custom Protein and Antibody Service
- Established research and production center in Nanjing, China
- GenScript Founded in New Jersey，US
Our Vision
Become the Most Trustworthy Biotech Company in the World
Our Mission
Make People and Nature Healthier Through Biotechnology
Key Facts
Frequently-Cited in
Publications
As of June 30, 2023, GenScript's products and services have been cited by 85,100 peer-reviewed journal
articles worldwide; placing GenScript among the most frequently-cited biotech companies in the
world.
Biologics CDMO
offers end-to-end CDMO services from drug discovery to commercialization with proactive strategies,
professional solutions and efficient processes in CGT, vaccine, biologics discovery and antibody protein
drug.
As the leading gene synthesis provider in the world, our gene synthesis tools are
designed
to make research accessible. Our propriety, population immune algorithm based GenSmart codon
optimization
technology enables the design of the most expression-efficient sequence available, while our CloneArk™
system provides a platform for researchers to archive, share and reuse their clones for future use with
peace of mind.
Powered by advanced PepPower™ synthesis technology platform and supported by stringent
quality management systems, GenScript synthesizes more than 25,000 peptides/month, featured with variety
of custom modifications, delivery options, and high level of batch-to-batch consistency
Powered by a unique B-cell cloning protocol, GenScript allows our clients to test for
antibodies that work in their application before sequencing the desired clones for recombinant antibody
production. Work with us to generate exclusive, custom rabbit monoclonal antibodies that are high in
sensitivity, affinity and specificity for your research and diagnostic needs.
Designed to accelerate the drug screening process, GenScript helps researchers identify
promising candidate leads and advance to the production of purified recombinant antibodies with one of
the
fastest turnaround times in the industry.
Through partnership with the technology's pioneering Broad Institute of MIT and Harvard,
as
well as ERS Genomics, GenScript offers a variety of CRISPR services, including guide RNA design tools,
pre-validated CRISPR plasmids, and learning resources to help scientists harness the power of CRISPR
genome editing in life science research.
